Plocamium Holdings

Novo Nordisk

ORG Health Care / Pharmaceuticals Primary: Attention Cascade

$70B market cap (Copenhagen-listed), Novo Nordisk manufactures diabetes, obesity, and cardiovascular drugs including blockbuster GLP-1 agonists Ozempic and Wegovy. Announced AI partnership with nference in November 2026 to accelerate cardiometabolic and aging research.

As of 2026-11-22, Plocamium Signal Index scores Novo Nordisk at -0.24 (NORMAL regime) with momentum 7.7 and 29 graph connections.

Strategic collaboration with nference to advance AI-driven research in cardiometabolic disease and healthy aging
PSI score
−0.24
Normal band, -1 to +1
7.7mid
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
100%
ConfidenceHow much of a full 30-day history the score rests on: daily observations divided by 30, up to 100%. Below 100% the score is pulled toward its sector average and scaled down in proportion.
29
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Novo Nordisk: getting more coverage than its own momentum predicts; an external catalyst is likely driving attention (primary driver: Attention Cascade).
Connected entities

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-11-22 ← Intelligence Network